Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q2 2020 · 10-Q
Revenue$5.40M$5.40M−68.0% vs Q2 2019 Net Income-$4.68M-$4.68MN/M vs Q2 2019 EPS Diluted-$0.05-$0.05N/M vs Q2 2019 Gross Profit$2,322,000−80.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,413,000N/M Free Cash Flowderived-$2,439,000N/M Margins · derivedGross margin43.0%−27.9 pt vs Q2 2019
Operating margin-86.3%−93.7 pt vs Q2 2019
Net margin-86.7%−94.0 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 7, 2020 · 38 d after period end